Progress in Neuro-Psychopharmacology and Biological Psychiatry
Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case–control and family based study designs
Introduction
Schizophrenia (SCZ) is a severe disabling neuropsychiatric disorder characterized by a collection of symptoms that may include positive symptoms such as paranoia and auditory hallucinations, negative symptoms including thought poverty, anhedonia, and social withdrawal, as well as cognitive impairment. It affects approximately 1% of the general population. Findings from family, twin, and adoption studies support a genetic basis for SCZ (reviewed in McGuffin et al., 1984), but its etiology is still unclear. Dopamine hypothesis of SCZ arose from the observations that dopamine-mimetic agents including amphetamine, induce SCZ associated symptoms, and that all antipsychotic medications have a certain degree of dopamine-blocking capacity.
D3 is a G-protein coupled receptor (GPCR) that, upon binding of dopamine, transduces signal via inhibition of cyclic Adenosine Mono-Phosphate (cAMP) synthesis. D3 is encoded by the DRD3 gene, which is located on chromosomal region 3q13.3. It is primarily expressed in the striatum, with the highest expression in the ventral portion. These brain regions have been implicated in SCZ pathophysiology. Ser9Gly is the only polymorphism that has been studied for its effects on D3 function. The Gly allele has been associated with increased binding affinity of dopamine (Lundstrom and Turpin, 1996), as well as increased dopamine-induced stimulation of Extracellular signal Regulated Kinase (ERK), an important intracellular signaling molecule involved in cell growth and differentiation, and inhibition of cAMP synthesis (Jeanneteau et al., 2006).
Researchers found decreased DRD3 (Sokoloff et al., 1990) mRNA expression in postmortem brain samples (Schmauss et al., 1993) and peripheral blood lymphocytes (Vogel et al., 2004) of SCZ patients compared to those of controls. The decrease could be due to increased splicing of the 3′ region of the DRD3 pre-mRNA (Schmauss, 1996), leading to an increased ratio of truncated (D3nf) to full-length (D3) mRNA. In contrast, Ilani et al. (2001) found increased DRD3 mRNA levels in SCZ patients' blood lymphocytes compared to controls. The mixed results could be due to different housekeeping genes used (Ilani et al., 2001, Vogel et al., 2004). It is noteworthy that the influence of antipsychotic medication at the time of death could also have accounted for these discrepancies. In this regard, Gurevich et al. (1997) found increased D3 levels in the ventral striatum of antipsychotic-free SCZ patients at the time of death, but similar D3 levels in SCZ patients taking antipsychotics up to the time of death. These results suggest that while D3 is up-regulated in SCZ, antipsychotics down-regulate it.
In the original genetic study of DRD3 in SCZ, Crocq et al. (1992) found Ser9Gly to be associated with SCZ using two matched case–control samples from France and the UK. Mant et al. (1994) from the same research group updated the positive findings with additional subjects, with an excess of the lower functioning Ser allele and Ser/Ser genotype in SCZ cases compared to controls. Our laboratory replicated the original positive findings using two independent samples from North America and Italy (Kennedy et al., 1995). The positive findings were also replicated in other independent samples (Shaikh et al., 1996, Spurlock et al., 1998, Ishiguro et al., 2000). However, they were challenged by results from many other studies, including the most recent meta-analyses (Ma et al., 2008, Utsunomiya et al., 2008).
Despite having accumulated genotype data from over 10,000 SCZ patients across different studies, with most studies having tested only the Ser9Gly polymorphism within this 50-kb gene, the role of DRD3 in SCZ remains elusive. Recently, Talkowski et al. (2006) investigated 11 polymorphisms evenly distributed within and around DRD3 for association with SCZ in two family samples (US and Indian) and a case–control sample. They found consistent association between Ser9Gly and SCZ in both family samples, but only against a common haplotype background (Talkowski et al., 2006). Dominguez and coworkers (2007) genotyped 17 polymorphisms spanning DRD3 and found haplotypes in the 3′ portion of the gene to be significantly associated in a Galician isolate population. These latest findings suggest that Ser9Gly may be a marker for other polymorphism(s) that confer risk to SCZ and encourage further more comprehensive examination of DRD3 in SCZ.
The brain-derived neurotrophic factor (BDNF) plays a critical role in dopaminergic neuronal establishment (Baquet et al., 2005). The number of tyrosine hydroxylase-expressing dopaminergic neurons was reduced in the midbrain–hindbrain regions where the BDNF gene was selectively deleted (Baquet et al., 2005). BDNF also specifically regulates the in-vivo expression of DRD3 in the nucleus accumbens both during development and in adulthood (Guillin et al., 2001). Postmortem studies in the brains of SCZ patients showed decreases in BDNF protein (Iritani et al., 2003, Weickert et al., 2003) and mRNA levels (Weickert et al., 2003), while Buckley et al., 2007, Palomino et al., 2006 recently found decreased plasma BDNF levels in first-episode patients. However, Takahashi et al. (2000) found increased BDNF protein levels in the hippocampus and nucleus accumbens in SCZ subjects. SCZ patients who were chronically on antipsychotic medications showed increased (Gama et al., 2007) or decreased (Grillo et al., 2007, Toyooka et al., 2002) serum BDNF levels compared to healthy controls. Similar BDNF levels between the chronically treated SCZ and controls were also reported (Shimizu et al., 2003). The mixed results could be due to a number of factors, including insufficient sample sizes, different patient populations, different brain regions examined, or different antipsychotics at different doses. Genetically, carriers of the BDNF Met66 allele have lower cognitive abilities of learning and memory associated with lower hippocampal activation compared to ValVal carriers (Egan et al., 2003). The mechanism of action could be reduced Met66-BDNF protein packaging and secretion from neurons compared to Val66-BDNF (Egan et al., 2003, Chen et al., 2004). The Met66 allele has also been associated with hippocampal volume (Pezawas et al., 2004). Five recent meta-analyses on Val66Met did not find a significant association with SCZ (Naoe et al., 2007, Qian et al., 2007, Xu et al., 2007a, Kanazawa et al., 2007, Zintzaras, 2007). The C270T polymorphism has also been analyzed in two meta-analyses, which found weak (Zintzaras, 2007) or no (Xu et al., 2007a) association with SCZ. However, the role of the BDNF gene could not be excluded as Qian et al. (2007) found a four-marker haplotype to be protective against SCZ in their Chinese sample. These results suggest that polymorphisms other than Val66Met and C207T may be involved in SCZ.
In the present study, we tested for the possibility of an association of tag polymorphisms in the DRD3 and BDNF genes with SCZ. We analyzed individual polymorphisms, as well as two-marker and three-marker haplotypes in a sliding window approach on our Caucasian paired case–control and small nuclear-family samples. In view of the substantive evidence that suggests a functional relationship between DRD3 and BDNF, we also examined their single-marker interactions for association with SCZ.
Section snippets
Subjects
The research subjects were recruited at the Centre for Addiction and Mental Health, except for eight triads that were recruited from the National Institute of Mental Health. Clearance from the institutional ethics committee and informed consent was obtained for all patients. We have included only Caucasian subjects in this study, as indicated by self-reported ancestries of grandparents. Two non-overlapping samples were analyzed in the present study. The case–control sample consists of 167
Sample characteristics
Genotypes of all the tag DRD3 and BDNF polymorphisms did not differ significantly from Hardy–Weinberg equilibrium for both the Caucasian paired case–control and family samples (p > 0.05). Haplotype analysis did not yield significant findings.
DRD3 and BDNF polymorphisms are not associated with SCZ
Upon testing for allele and genotype frequency distribution differences in our matched SCZ case–control sample, we found rs7633291 CC genotype [ORCC = 0.22; 95% confidence interval (CI): 0.06–0.78] and rs1025398 A allele [ORA = 0.71; 95% CI: 0.52–0.99] to be
Discussion
The current study on a nuclear-family sample and an independent paired case–control sample reports no statistically significant association of the DRD3 and BDNF genes with SCZ. We find nominally significant associations with a number of polymorphisms. In particular, we observe suggestive results for DRD3 rs7633291 in both case–control and family samples. However, the risk alleles differ between the samples. This polymorphism also shows pairwise interaction with BDNF rs7934165 in SCZ diagnosis.
Acknowledgements
Funding sources include CIHR-postdoctoral fellowship to AKT; CIHR operational grants to JLK and DJM; NARSAD grants to DJM, MH41468, the Prentiss Foundation, Ritter Foundation, Hintz family, and the Peterson Family to HYM. The CR Younger Foundation and Bebensee Foundation to CCZ. We thank Glaxo-Smith-Kline for funding part of the genoytyping costs. We also thank the participants in this study.
References (62)
- et al.
Brain derived neurotropic factor in first-episode psychosis
Schizophr Res
(2007) - et al.
Extensive linkage disequilibrium mapping at HTR2A and DRD3 for schizophrenia susceptibility genes in the Galician population
Schizophr Res
(2007) - et al.
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function
Cell
(2003) - et al.
Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder
Neurosci Lett
(2007) - et al.
Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics
J Psychiatry Res
(2007) - et al.
Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains
Prog Neuropsychopharmacol Biol Psychiatry
(2003) - et al.
Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest Virus System
Biochem Biophys Res Comm
(1996) - et al.
The Ser9Gly polymorphism of the dopamine D3 receptor gene and risk of schizophrenia: an association study and a large meta-analysis
Schizophr Res
(2008) - et al.
No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: evidence from a case–control study and meta-analysis
Neurosci Lett
(2007) - et al.
Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients
Schizophr Res
(2006)
Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis
Biochem Biophys Res Comm
Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression
Biol Psychiatry
Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls
Neurosci Lett
NRG1 and BDNF genes in schizophrenia: an association study in an Italian case–control sample
Psychiatry Res
Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples
Biol Psychiatry
Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients
Psychiatry Res
Genetic association between the dopamine D3 gene polymorphism (Ser9Gly) and schizophrenia in Japanese populations: evidence from a case–control study and meta-analysis
Neurosci Lett
Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis
Schizophr Res
Genetic study of eight AKT1 Gene polymorphisms and their interaction with DRD2 Gene polymorphisms in tardive dyskinesia
Schizophr Res
Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia
Eur Neuropsychopharmacol
Diagnostic and statistical manual of mental disorders
Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta
J Neurosci
Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wildtype BDNF in neurosecretory cells and cortical neurons
J Neurosci
A common haplotype of DRD3 affected by recent positive selection is associated with protection from schizophrenia
Hum Genet
Association between schizophrenia and homozygosity at the dopamine D3 receptor gene
J Med Genet
Pedigree disequilibrium tests for multilocus haplotypes
Genet Epidemiol
Structured Clinical Interview for DSM-IV Axis I and II Disorders
QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies
BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization
Nature
Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study
Arch Gen Psychiatry
Cited by (16)
Copy number variant syndromes are frequent in schizophrenia: Progressing towards a CNV-schizophrenia model
2019, Schizophrenia ResearchCitation Excerpt :DNA samples from 348 SCZ patients at the Centre for Addiction and Mental Health (CAMH, Toronto, Canada) were genetically analyzed in this study. The patient cohort, a subset of which was investigated in this study, was previously described (Zai et al., 2010). Briefly, the study cohort is primarily Caucasian, approximately two-thirds male, with an average age of 49.8 years at the time of recruitment; detailed demographic characteristics of the sample are shown in Supplementary Table S1.
Association study of BDNF and DRD3 genes with alcohol use disorder in Schizophrenia
2018, Neuroscience LettersCitation Excerpt :In addition, few studies explored the role of BDNF and DRD3 in the context of comorbid AUD and other psychiatric disorders such as schizophrenia. This is particularly relevant given that BDNF and DRD3 may be implicated in schizophrenia risk and prognosis [36–43]. Despite the potential role of BDNF and DRD3 in substance abuse as well as schizophrenia, few studies have examined these genes in the context of comorbid AUD and schizophrenia.
NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy
2016, Epilepsy and BehaviorInteraction of the DRD3 and BDNF gene variants in subtyped bipolar disorder
2012, Progress in Neuro-Psychopharmacology and Biological PsychiatryThe role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain
2012, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :SNPs were selected based on functional significance (Val-66-Met) and coverage of the BDNF gene. They were included in previous genetic studies of schizophrenia and tardive dyskinesia (Zai et al., 2009, 2010). For the rs7934165 (Assays-on-Demand Assay ID: C_1197567_10), rs11030104 (C_1751792_10), Val66Met (rs6265; C_11592758_10), and rs1519480 (C_11592757_20) markers, genotypes were assessed by the TaqMan allele specific assay method using the ABI Prism®7500 Sequence Detection System according to the manufacturer's protocols (Applied Biosystems Inc., Foster City, CA) with the reaction mixture in a total volume of 10 μl, consisting of 20 ng of genomic DNA, 2X TaqMan Universal Master Mix, and 40X SNP Genotyping Assay Mix (Applied Biosystems Inc.).